{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:19:40Z","timestamp":1794359980891,"version":"4.9.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:00:00Z","timestamp":1794355200000},"content-version":"vor","delay-in-days":114,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Mayo Edward C. Kendall Fellowship in Biochemistry","award":["No specific grant number"],"award-info":[{"award-number":["No specific grant number"]}]},{"DOI":"10.13039\/100001287","name":"Elsa U. Pardee Foundation","doi-asserted-by":"publisher","award":["No specific grant number"],"award-info":[{"award-number":["No specific grant number"]}],"id":[{"id":"10.13039\/100001287","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Atossa Therapeutics, Inc.","award":["No specific grant number"],"award-info":[{"award-number":["No specific grant number"]}],"id":[{"id":"https:\/\/ror.org\/03yqekx34","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-026-01007-x","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:08:28Z","timestamp":1784574508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ER\u03b1+ breast cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Lena","family":"Batoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev S.","family":"Muthyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Rodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Emch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Marigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Detry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra S.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Sadatrezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Quay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Hawse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1007_CR1","doi-asserted-by":"publisher","first-page":"djv048","DOI":"10.1093\/jnci\/djv048","volume":"107","author":"BA Kohler","year":"2015","unstructured":"Kohler, B. A. et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race\/ethnicity, poverty, and state. J. Natl. Cancer Inst. 107, djv048 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"1007_CR2","doi-asserted-by":"crossref","unstructured":"Dumas, E. et al. Explaining the relationships between age, endocrine therapy persistence, and risk of recurrence in hormone receptor-positive early breast cancer: a nationwide cohort study. J. Clin. Oncol. Jco2401131 (2025).","DOI":"10.1200\/JCO.24.01131"},{"key":"1007_CR3","doi-asserted-by":"publisher","first-page":"102375","DOI":"10.1016\/j.ctrv.2022.102375","volume":"105","author":"AJ Kerr","year":"2022","unstructured":"Kerr, A. J. et al. Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality. Cancer Treat. Rev. 105, 102375 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"1007_CR4","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO.21.02844","volume":"40","author":"A Johansson","year":"2022","unstructured":"Johansson, A. et al. Twenty-year benefit from adjuvant goserelin and tamoxifen in premenopausal patients with breast cancer in a controlled randomized clinical trial. J. Clin. Oncol. 40, 4071\u20134082 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1007_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Prim. 5, 66 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1007_CR6","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/S0140-6736(16)32419-9","volume":"389","author":"NC Turner","year":"2017","unstructured":"Turner, N. C., Neven, P., Loibl, S. & Andre, F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet 389, 2403\u20132414 (2017).","journal-title":"Lancet"},{"key":"1007_CR7","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H. et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836\u20131846 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1007_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34, 427\u2013438.e426 (2018).","journal-title":"Cancer Cell"},{"key":"1007_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41416-023-02158-5","volume":"128","author":"A Howell","year":"2023","unstructured":"Howell, A. & Howell, S. J. Tamoxifen evolution. Br. J. Cancer 128, 421\u2013425 (2023).","journal-title":"Br. J. Cancer"},{"key":"1007_CR10","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1056\/NEJMra1307118","volume":"383","author":"HJ Burstein","year":"2020","unstructured":"Burstein, H. J. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N. Engl. J. Med. 383, 2557\u20132570 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1007_CR11","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","volume":"125","author":"D Dustin","year":"2019","unstructured":"Dustin, D., Gu, G. & Fuqua, S. A. W. ESR1 mutations in breast cancer. Cancer 125, 3714\u20133728 (2019).","journal-title":"Cancer"},{"key":"1007_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/17512433.2019.1610390","volume":"12","author":"AB Sanchez-Spitman","year":"2019","unstructured":"Sanchez-Spitman, A. B. et al. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Expert Rev. Clin. Pharm. 12, 523\u2013536 (2019).","journal-title":"Expert Rev. Clin. Pharm."},{"key":"1007_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/sj.clpt.6100367","volume":"83","author":"MP Goetz","year":"2008","unstructured":"Goetz, M. P., Kamal, A. & Ames, M. M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin. Pharm. Ther. 83, 160\u2013166 (2008).","journal-title":"Clin. Pharm. Ther."},{"key":"1007_CR14","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1158\/0008-5472.CAN-08-3933","volume":"69","author":"X Wu","year":"2009","unstructured":"Wu, X. et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 69, 1722\u20131727 (2009).","journal-title":"Cancer Res."},{"key":"1007_CR15","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jama.2009.1420","volume":"302","author":"W Schroth","year":"2009","unstructured":"Schroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. J. Am. Med. Assoc. 302, 1429\u20131436 (2009).","journal-title":"J. Am. Med. Assoc."},{"key":"1007_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/clpt.2013.186","volume":"95","author":"MA Province","year":"2014","unstructured":"Province, M. A. et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin. Pharm. Ther. 95, 216\u2013227 (2014).","journal-title":"Clin. Pharm. Ther."},{"key":"1007_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00606-2","volume":"9","author":"S Jayaraman","year":"2023","unstructured":"Jayaraman, S. et al. Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ER\u03b1+ breast cancer. NPJ Breast Cancer 9, 101 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"1007_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/1541-7786.MCR-20-0872","volume":"19","author":"CJ Jones","year":"2021","unstructured":"Jones, C. J. et al. Development and characterization of novel endoxifen-resistant breast cancer cell lines highlight numerous differences from tamoxifen-resistant models. Mol. Cancer Res. 19, 1026\u20131039 (2021).","journal-title":"Mol. Cancer Res."},{"key":"1007_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01286-7","volume":"22","author":"S Jayaraman","year":"2020","unstructured":"Jayaraman, S. et al. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Res. 22, 51 (2020).","journal-title":"Breast Cancer Res."},{"key":"1007_CR20","doi-asserted-by":"publisher","first-page":"e54613","DOI":"10.1371\/journal.pone.0054613","volume":"8","author":"JR Hawse","year":"2013","unstructured":"Hawse, J. R. et al. Endoxifen\u2019s molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS ONE 8, e54613 (2013).","journal-title":"PLoS ONE"},{"key":"1007_CR21","doi-asserted-by":"publisher","unstructured":"Jayaraman, S., Reid, J. M., Hawse, J. R. & Goetz, M. P. Endoxifen, an estrogen receptor targeted therapy: From bench to bedside. Endocrinology https:\/\/doi.org\/10.1210\/endocr\/bqab191 (2021).","DOI":"10.1210\/endocr\/bqab191"},{"key":"1007_CR22","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.2017.73.3246","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz, M. P. et al. First-in-Human phase I study of the tamoxifen metabolite Z-Endoxifen in women with endocrine-refractory metastatic breast cancer. J. Clin. Oncol. 35, 3391\u20133400 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1007_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.18632\/oncotarget.27887","volume":"12","author":"N Takebe","year":"2021","unstructured":"Takebe, N. et al. Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors. Oncotarget 12, 268\u2013277 (2021).","journal-title":"Oncotarget"},{"key":"1007_CR24","doi-asserted-by":"publisher","unstructured":"Goetz, M. et al. Abstract P1-11-04: Neoadjuvant Z-endoxifen for premenopausal estrogen receptor (ER)+, human epidermal growth factor receptor (HER2)- breast cancer (BC): evaluation of the pharmacokinetic (PK) run-in for the EVANGELINE study. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-p1-11-04 (2025).","DOI":"10.1158\/1557-3265.Sabcs24-p1-11-04"},{"key":"1007_CR25","doi-asserted-by":"publisher","unstructured":"Goetz, M. P. et al. Abstract PD7-06: a randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs19-pd7-06 (2020).","DOI":"10.1158\/1538-7445.Sabcs19-pd7-06"},{"key":"1007_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00523-4","volume":"9","author":"R Patel","year":"2023","unstructured":"Patel, R., Klein, P., Tiersten, A. & Sparano, J. A. An emerging generation of endocrine therapies in breast cancer: a clinical perspective. npj Breast Cancer 9, 20 (2023).","journal-title":"npj Breast Cancer"},{"key":"1007_CR27","doi-asserted-by":"publisher","first-page":"102569","DOI":"10.1016\/j.ctrv.2023.102569","volume":"117","author":"C Corti","year":"2023","unstructured":"Corti, C. et al. Novel endocrine therapies: what is next in estrogen receptor positive, HER2 negative breast cancer? Cancer Treat. Rev. 117, 102569 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"1007_CR28","doi-asserted-by":"publisher","first-page":"e31532","DOI":"10.1371\/annotation\/18f08a33-35e1-4bf9-8d21-476757dccbef","volume":"7","author":"JA Aka","year":"2012","unstructured":"Aka, J. A. & Lin, S. X. Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7. PLoS ONE 7, e31532 (2012).","journal-title":"PLoS ONE"},{"key":"1007_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01300-y","volume":"22","author":"J Finlay-Schultz","year":"2020","unstructured":"Finlay-Schultz, J. et al. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 22, 68 (2020).","journal-title":"Breast Cancer Res."},{"key":"1007_CR30","doi-asserted-by":"publisher","unstructured":"Romanazzo, S. et al. A biofabricated 3D cancer-stroma tumor microenvironment model. Biofabrication https:\/\/doi.org\/10.1088\/1758-5090\/ae0a82 (2025).","DOI":"10.1088\/1758-5090\/ae0a82"},{"key":"1007_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-749","volume":"14","author":"JM Reese","year":"2014","unstructured":"Reese, J. M. et al. ER\u03b21: characterization, prognosis, and evaluation of treatment strategies in ER\u03b1-positive and -negative breast cancer. BMC Cancer 14, 749 (2014).","journal-title":"BMC Cancer"},{"key":"1007_CR32","doi-asserted-by":"publisher","first-page":"1047166","DOI":"10.3389\/fmed.2023.1047166","volume":"10","author":"KGM Aspros","year":"2023","unstructured":"Aspros, K. G. M. et al. Disruption of estrogen receptor beta\u2019s DNA binding domain impairs its tumor suppressive effects in triple negative breast cancer. Front. Med. (Lausanne) 10, 1047166 (2023).","journal-title":"Front. Med. (Lausanne)"},{"key":"1007_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00387-0","volume":"8","author":"KGM Aspros","year":"2022","unstructured":"Aspros, K. G. M. et al. Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF\u03baB\/p65 signaling in triple negative breast cancer. NPJ Breast Cancer 8, 20 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"1007_CR34","doi-asserted-by":"publisher","first-page":"E9580","DOI":"10.1073\/pnas.1807751115","volume":"115","author":"JM Reese","year":"2018","unstructured":"Reese, J. M. et al. ER\u03b2-mediated induction of cystatins results in suppression of TGF\u03b2 signaling and inhibition of triple-negative breast cancer metastasis. Proc. Natl. Acad. Sci. USA 115, E9580\u2013e9589 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1007_CR35","doi-asserted-by":"publisher","first-page":"96506","DOI":"10.18632\/oncotarget.21787","volume":"8","author":"JM Reese","year":"2017","unstructured":"Reese, J. M. et al. ER\u03b2 inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. Oncotarget 8, 96506\u201396521 (2017).","journal-title":"Oncotarget"},{"key":"1007_CR36","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1210\/me.2004-0164","volume":"18","author":"M Fan","year":"2004","unstructured":"Fan, M., Nakshatri, H. & Nephew, K. P. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol. Endocrinol. 18, 2603\u20132615 (2004).","journal-title":"Mol. Endocrinol."},{"key":"1007_CR37","doi-asserted-by":"publisher","first-page":"115739","DOI":"10.1016\/j.ejca.2025.115739","volume":"228","author":"C Valenza","year":"2025","unstructured":"Valenza, C. & Curigliano, G. Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer. Eur. J. Cancer 228, 115739 (2025).","journal-title":"Eur. J. Cancer"},{"key":"1007_CR38","doi-asserted-by":"publisher","unstructured":"Hu, J., Zhong, S., Sun, H., Liu, J. & Fang, W. Advances and challenges of estrogen receptor-targeted agents in breast cancer. Arch. Pharm. Res. https:\/\/doi.org\/10.1007\/s12272-025-01583-9 (2025).","DOI":"10.1007\/s12272-025-01583-9"},{"key":"1007_CR39","doi-asserted-by":"publisher","first-page":"1498141","DOI":"10.3389\/fbioe.2025.1498141","volume":"13","author":"Y Zhou","year":"2025","unstructured":"Zhou, Y., Yu, F., Guo, M., Tang, Y. & Xu, Q. Bridging the gap: the role of 3D cell cultures in mimicking tumor microenvironment for enhanced drug testing accuracy. Front. Bioeng. Biotechnol. 13, 1498141 (2025).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"1007_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2270-9","volume":"16","author":"T Ueno","year":"2016","unstructured":"Ueno, T. et al. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. BMC Cancer 16, 230 (2016).","journal-title":"BMC Cancer"},{"key":"1007_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41419-024-06539-3","volume":"15","author":"T Yang","year":"2024","unstructured":"Yang, T. et al. A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER\u2212 cells via endoplasmic reticulum stress-induced apoptosis. Cell Death Dis. 15, 147 (2024).","journal-title":"Cell Death Dis."},{"key":"1007_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bone.2016.03.016","volume":"87","author":"AB Khalid","year":"2016","unstructured":"Khalid, A. B. & Krum, S. A. Estrogen receptors alpha and beta in bone. Bone 87, 130\u2013135 (2016).","journal-title":"Bone"},{"key":"1007_CR43","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1073\/pnas.0602194103","volume":"103","author":"A Morani","year":"2006","unstructured":"Morani, A. et al. Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-\/-) mice. Proc. Natl. Acad. Sci. USA 103, 7165\u20137169 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1007_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41723-7","volume":"14","author":"N Itoh","year":"2023","unstructured":"Itoh, N. et al. Estrogen receptor beta in astrocytes modulates cognitive function in mid-age female mice. Nat. Commun. 14, 6044 (2023).","journal-title":"Nat. Commun."},{"key":"1007_CR45","doi-asserted-by":"publisher","first-page":"e98219","DOI":"10.1371\/journal.pone.0098219","volume":"9","author":"A Gingery","year":"2014","unstructured":"Gingery, A. et al. The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton. PLoS ONE 9, e98219 (2014).","journal-title":"PLoS ONE"},{"key":"1007_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-22034-x","volume":"15","author":"A Shneyderman","year":"2025","unstructured":"Shneyderman, A. et al. Evaluation of (Z)-endoxifen as a potential therapy for glioblastoma multiforme through computational and experimental analyses. Sci. Rep. 15, 38225 (2025).","journal-title":"Sci. Rep."},{"key":"1007_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-0716-3882-8_7","volume":"2811","author":"HM Quinn","year":"2024","unstructured":"Quinn, H. M., Battista, L., Scabia, V. & Brisken, C. Preclinical mouse intraductal model (MIND) to study metastatic dormancy in estrogen receptor-positive breast cancer. Methods Mol. Biol. 2811, 101\u2013112 (2024).","journal-title":"Methods Mol. Biol."},{"key":"1007_CR48","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41388-017-0036-8","volume":"37","author":"A Martinez-Ordo\u00f1ez","year":"2018","unstructured":"Martinez-Ordo\u00f1ez, A. et al. Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis. Oncogene 37, 1430\u20131444 (2018).","journal-title":"Oncogene"},{"key":"1007_CR49","doi-asserted-by":"publisher","unstructured":"Chen, C. Y. et al. Cancer-associated-fibroblast-mediated paracrine and autocrine SDF-1\/CXCR4 signaling promotes stemness and aggressiveness of colorectal cancers. Cells https:\/\/doi.org\/10.3390\/cells13161334 (2024).","DOI":"10.3390\/cells13161334"},{"key":"1007_CR50","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1038\/s41388-019-0773-y","volume":"38","author":"A Bernat-Peguera","year":"2019","unstructured":"Bernat-Peguera, A. et al. PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma. Oncogene 38, 5021\u20135037 (2019).","journal-title":"Oncogene"},{"key":"1007_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.12659\/MSM.899319","volume":"23","author":"Z Song","year":"2017","unstructured":"Song, Z. et al. High expression of stromal cell-derived factor 1 (SDF-1) and NF-\u03baB predicts poor prognosis in cervical cancer. Med. Sci. Monit. 23, 151\u2013157 (2017).","journal-title":"Med. Sci. Monit."},{"key":"1007_CR52","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1182\/blood-2004-11-4349","volume":"105","author":"A Kortesidis","year":"2005","unstructured":"Kortesidis, A. et al. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 105, 3793\u20133801 (2005).","journal-title":"Blood"},{"key":"1007_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2143-2","volume":"16","author":"M Mego","year":"2016","unstructured":"Mego, M. et al. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. BMC Cancer 16, 127 (2016).","journal-title":"BMC Cancer"},{"key":"1007_CR54","doi-asserted-by":"publisher","first-page":"R402","DOI":"10.1186\/bcr1022","volume":"7","author":"H Kang","year":"2005","unstructured":"Kang, H. et al. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res. 7, R402\u2013R410 (2005).","journal-title":"Breast Cancer Res."},{"key":"1007_CR55","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.2337\/db07-0291","volume":"56","author":"T Yano","year":"2007","unstructured":"Yano, T., Liu, Z., Donovan, J., Thomas, M. K. & Habener, J. F. Stromal cell derived factor-1 (SDF-1)\/CXCL12 attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt. Diabetes 56, 2946\u20132957 (2007).","journal-title":"Diabetes"},{"key":"1007_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cytogfr.2023.10.003","volume":"75","author":"DP Anastasiadou","year":"2024","unstructured":"Anastasiadou, D. P., Quesnel, A., Duran, C. L., Filippou, P. S. & Karagiannis, G. S. An emerging paradigm of CXCL12 involvement in the metastatic cascade. Cytokine Growth Factor Rev. 75, 12\u201330 (2024).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1007_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/srep39541","volume":"6","author":"L Ouyang","year":"2016","unstructured":"Ouyang, L. et al. Estrogen-induced SDF-1\u03b1 production promotes the progression of ER-negative breast cancer via the accumulation of MDSCs in the tumor microenvironment. Sci. Rep. 6, 39541 (2016).","journal-title":"Sci. Rep."},{"key":"1007_CR58","doi-asserted-by":"publisher","unstructured":"Sala-Gaston, J. et al. HERC ubiquitin ligases in cancer. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12061653 (2020).","DOI":"10.3390\/cancers12061653"},{"key":"1007_CR59","doi-asserted-by":"publisher","first-page":"120692","DOI":"10.1016\/j.lfs.2022.120692","volume":"303","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. HERC5\/IFI16\/p53 signaling mediates breast cancer cell proliferation and migration. Life Sci. 303, 120692 (2022).","journal-title":"Life Sci."},{"key":"1007_CR60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41419-022-04511-7","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. HERC3 regulates epithelial-mesenchymal transition by directly ubiquitination degradation EIF5A2 and inhibits metastasis of colorectal cancer. Cell Death Dis. 13, 74 (2022).","journal-title":"Cell Death Dis."},{"key":"1007_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00190-9","volume":"6","author":"AR Michmerhuizen","year":"2020","unstructured":"Michmerhuizen, A. R., Spratt, D. E., Pierce, L. J. & Speers, C. W. ARe we there yet? Understanding androgen receptor signaling in breast cancer. npj Breast Cancer 6, 47 (2020).","journal-title":"npj Breast Cancer"},{"key":"1007_CR62","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41591-020-01168-7","volume":"27","author":"TE Hickey","year":"2021","unstructured":"Hickey, T. E. et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat. Med. 27, 310\u2013320 (2021).","journal-title":"Nat. Med."},{"key":"1007_CR63","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1158\/0008-5472.CAN-22-1016","volume":"83","author":"L Wei","year":"2023","unstructured":"Wei, L. et al. Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer. Cancer Res. 83, 456\u2013470 (2023).","journal-title":"Cancer Res."},{"key":"1007_CR64","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1470-2045(24)00004-4","volume":"25","author":"C Palmieri","year":"2024","unstructured":"Palmieri, C. et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 25, 317\u2013325 (2024).","journal-title":"Lancet Oncol."},{"key":"1007_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-03161-y","volume":"25","author":"L Hosseinzadeh","year":"2024","unstructured":"Hosseinzadeh, L. et al. The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer. Genome Biol. 25, 44 (2024).","journal-title":"Genome Biol."},{"key":"1007_CR66","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41416-021-01478-8","volume":"125","author":"TE Hickey","year":"2021","unstructured":"Hickey, T. E., Dwyer, A. R. & Tilley, W. D. Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer. Br. J. Cancer 125, 1599\u20131601 (2021).","journal-title":"Br. J. Cancer"},{"key":"1007_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0851-4","volume":"19","author":"A Bahreini","year":"2017","unstructured":"Bahreini, A. et al. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Res. 19, 60 (2017).","journal-title":"Breast Cancer Res."},{"key":"1007_CR68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"1007_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-015-0611-3","volume":"16","author":"H Heberle","year":"2015","unstructured":"Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P. & Minghim, R. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinforma. 16, 169 (2015).","journal-title":"BMC Bioinforma."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01007-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01007-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01007-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:05:12Z","timestamp":1794355512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01007-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-01007-x","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Atossa Therapeutics, Inc. funded research activities related to this study and provided ENDX and the NCEs. SSH and MS are employees of Atossa Therapeutics and receive salary from the company. SCQ is Chief Executive Officer of Atossa Therapeutics and holds patents related to ENDX. The authors report no competing interest related to this work other than the funding and disclosures stated above.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"143"}}